Vol 14, No 1 (2021)
Guidelines / Expert consensus
Published online: 2021-10-06

open access

Page views 6049
Article views/downloads 472
Get Citation

Connect on Social Media

Connect on Social Media

Polish Society of Nephrology Working Group — management of pregnant women with chronic kidney disease

Magdalena Durlik1, Marcin Adamczak, Ilona Kurnatowska, Tomasz Stompór
Renal Disease and Transplantation Forum 2021;14(1).

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Gonzalez Suarez ML, Kattah A, Grande JP, et al. Renal Disorders in Pregnancy: Core Curriculum 2019. Am J Kidney Dis. 2019; 73(1): 119–130.
  2. Piccoli GB, Zakharova E, Attini R, et al. Pregnancy in Chronic Kidney Disease: Need for Higher Awareness. A Pragmatic Review Focused on What Could Be Improved in the Different CKD Stages and Phases. J Clin Med. 2018; 7(11).
  3. Wiles KS, Nelson-Piercy C, Bramham K, et al. Pre-pregnancy counselling for women with chronic kidney disease: a retrospective analysis of nine years' experience. BMC Nephrol. 2015; 16(3): 28–184.
  4. Piccoli GB, Attini R, Vasario E, et al. Pregnancy and chronic kidney disease: a challenge in all CKD stages. Clin J Am Soc Nephrol. 2010; 5(5): 844–855.
  5. Zhang JJ, Ma XX, Hao Li, et al. A Systematic Review and Meta-Analysis of Outcomes of Pregnancy in CKD and CKD Outcomes in Pregnancy. Clin J Am Soc Nephrol. 2015; 10(11): 1964–1978.
  6. Piccoli GB, Cabiddu G, Attini R, et al. Risk of Adverse Pregnancy Outcomes in Women with CKD. J Am Soc Nephrol. 2015; 26(8): 2011–2022.
  7. Gruber MF. Food and Drug Administration, HHS. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule. Fed Regist. 2014; 79(233): 72063–72103.
  8. Ponticelli C, Moroni G. Fetal Toxicity of Immunosuppressive Drugs in Pregnancy. J Clin Med. 2018; 7(12).
  9. Immunosuppressants. Reactions Weekly. 2018; 1732(1): 196–196.
  10. Hebert MF, Zheng S, Hays K, et al. Interpreting tacrolimus concentrations during pregnancy and postpartum. Transplantation. 2013; 95(7): 908–915.
  11. King RW, Baca MJ, Armenti VT, et al. Pregnancy Outcomes Related to Mycophenolate Exposure in Female Kidney Transplant Recipients. Am J Transplant. 2017; 17(1): 151–160.
  12. Tykarski A, Filipiak KJ, Januszewicz A, et al. Zasady postępowania w nadciśnieniu tętniczym — 2019 rok. Wytyczne Polskiego Towarzystwa nienia iczego. Nadciś Tętn Prakt. 2019; 5: 1–84.
  13. Prejbisz A, Dobrowolski P, Kosiński P, et al. Management of hypertension in pregnancy: prevention, diagnosis, treatment and long‑term prognosis. Kardiol Pol. 2019; 77(7-8): 757–806.
  14. Piccoli GB, Cabiddu G, Attini R, et al. Hypertension in CKD Pregnancy: a Question of Cause and Effect (Cause or Effect? This Is the Question). Curr Hypertens Rep. 2016; 18(5): 35.
  15. Hall M. Pregnancy in Women With CKD: A Success Story. Am J Kidney Dis. 2016; 68(4): 633–639.
  16. Gonzalez Suarez ML, Kattah A, Grande JP, et al. Renal Disorders in Pregnancy: Core Curriculum 2019. Am J Kidney Dis. 2019; 73(1): 119–130.
  17. Krane NK, Hamrahian M. Pregnancy: kidney diseases and hypertension. Am J Kidney Dis. 2007; 49(2): 336–345.
  18. Zhang JJ, Ma XX, Hao Li, et al. A Systematic Review and Meta-Analysis of Outcomes of Pregnancy in CKD and CKD Outcomes in Pregnancy. Clin J Am Soc Nephrol. 2015; 10(11): 1964–1978.
  19. Bateman BT, Bansil P, Hernandez-Diaz S, et al. Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions. Am J Obstet Gynecol. 2012; 206(2): 134.e1–134.e8.
  20. Coca Payeras A, Williams B, Mancia G, et al. ESC Scientific Document Group . 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021–3104.
  21. Bello NA, Miller E, Cleary K, et al. Out of Office Blood Pressure Measurement in Pregnancy and the Postpartum Period. Curr Hypertens Rep. 2018; 20(12): 101.
  22. Magee LA, von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015; 372(5): 407–417.
  23. Webster LM, Conti-Ramsden F, Seed PT, et al. Impact of Antihypertensive Treatment on Maternal and Perinatal Outcomes in Pregnancy Complicated by Chronic Hypertension: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017; 6(5).
  24. Magee LA, von Dadelszen P, Singer J, et al. CHIPS Study Group*. The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure? Hypertension. 2016; 68(5): 1153–1159.
  25. Silversides CK, Grewal J, Mason J, et al. Cardiac Disease in Pregnancy (CARPREG) Investigators. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. 2001; 104(5): 515–521.
  26. Hanson MA, Bardsley A, De-Regil LM, et al. The International Federation of Gynecology and Obstetrics (FIGO) recommendations on adolescent, preconception, and maternal nutrition: "Think Nutrition First". Int J Gynaecol Obstet. 2015; 131 Suppl 4: S213–S253.
  27. Cockburn J, Ounsted M, Moar VA, et al. FINAL REPORT OF STUDY ON HYPERTENSION DURING PREGNANCY: THE EFFECTS OF SPECIFIC TREATMENT ON THE GROWTH AND DEVELOPMENT OF THE CHILDREN. The Lancet. 1982; 319(8273): 647–649.
  28. Hoeltzenbein M, Beck E, Fietz AK, et al. Pregnancy Outcome After First Trimester Use of Methyldopa: A Prospective Cohort Study. Hypertension. 2017; 70(1): 201–208.
  29. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203 Summary: Chronic Hypertension in Pregnancy. Obstet Gynecol. 2019; 133(1): 215–219.
  30. Clark SM, Dunn HE, Hankins GDV. A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy. Semin Perinatol. 2015; 39(7): 548–555.
  31. Kurtzman JL, Thorp JM, Spielman FJ, et al. Do nifedipine and verapamil potentiate the cardiac toxicity of magnesium sulfate? Am J Perinatol. 1993; 10(6): 450–452.
  32. Magee LA, von Dadelszen P, Singer J, et al. CHIPS Study Group. Control of Hypertension In Pregnancy Study randomised controlled trial-are the results dependent on the choice of labetalol or methyldopa? BJOG. 2016; 123(7): 1135–1141.
  33. Magee LA, Pels A, Helewa M, et al. SOGC Hypertension Guideline Committee, Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014; 36(5): 416–441.
  34. Krane NK, Hamrahian M. Pregnancy: kidney diseases and hypertension. Am J Kidney Dis. 2007; 49(2): 336–345.
  35. Piccoli GB, Cabiddu G, Attini R, et al. Risk of Adverse Pregnancy Outcomes in Women with CKD. J Am Soc Nephrol. 2015; 26(8): 2011–2022.
  36. Blom K, Odutayo A, Bramham K, et al. Pregnancy and Glomerular Disease: A Systematic Review of the Literature with Management Guidelines. Clin J Am Soc Nephrol. 2017; 12(11): 1862–1872.
  37. Wang F, Lu JD, Zhu Y, et al. Renal Outcomes of Pregnant Patients with Immunoglobulin A Nephropathy: A Systematic Review and Meta-Analysis. Am J Nephrol. 2019; 49(3): 214–224.
  38. Gonzalez Suarez ML, Kattah A, Grande JP, et al. Renal Disorders in Pregnancy: Core Curriculum 2019. Am J Kidney Dis. 2019; 73(1): 119–130.
  39. Li Y, Wang W, Wang Y, et al. Fetal Risks and Maternal Renal Complications in Pregnancy with Preexisting Chronic Glomerulonephritis. Med Sci Monit. 2018; 24: 1008–1016.
  40. De Castro I, Easterling TR, Bansal N, et al. Nephrotic syndrome in pregnancy poses risks with both maternal and fetal complications. Kidney Int. 2017; 91(6): 1464–1472.
  41. Oliverio AL, Zee J, Mariani LH, et al. Renal Complications in Pregnancy Preceding Glomerulonephropathy Diagnosis. Kidney Int Rep. 2019; 4(1): 159–162.
  42. Hladunewich MA, Bramham K, Jim B, et al. Managing glomerular disease in pregnancy. Nephrol Dial Transplant. 2017; 32(suppl_1): i48–i56.
  43. Wiles K, Chappell L, Clark K, et al. Clinical practice guideline on pregnancy and renal disease. BMC Nephrol. 2019; 20(1): 401.
  44. Wiles KS, Nelson-Piercy C, Bramham K, et al. Pre-pregnancy counselling for women with chronic kidney disease: a retrospective analysis of nine years' experience. BMC Nephrol. 2015; 16(3): 28–184.
  45. Barbour SJ, Greenwald A, Djurdjev O, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012; 81(2): 190–195.
  46. Basude S, Hein C, Curtis SL, et al. Low-molecular-weight heparin or warfarin for anticoagulation in pregnant women with mechanical heart valves: what are the risks? A retrospective observational study. BJOG. 2012; 119(8): 1008–13; discussion 1012.
  47. Kamel H, Navi BB, Sriram N, et al. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med. 2014; 370(14): 1307–1315.
  48. Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ. 2015; 350: h1035.
  49. Colla L, Diena D, Rossetti M, et al. Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era. J Nephrol. 2018; 31(3): 361–383.
  50. Webster P, Lightstone L, McKay DB, et al. Pregnancy in chronic kidney disease and kidney transplantation. Kidney Int. 2017; 91(5): 1047–1056.
  51. Shah S, Verma P. Overview of Pregnancy in Renal Transplant Patients. Int J Nephrol. 2016; 2016: 4539342.
  52. Garcia-Donaire JA, Acevedo M, Gutiérrez MJ, et al. Tacrolimus as basic immunosuppression in pregnancy after renal transplantation. A single-center experience. Transplant Proc. 2005; 37(9): 3754–3755.
  53. Zheng S, Easterling TR, Umans JG, et al. Pharmacokinetics of tacrolimus during pregnancy. Ther Drug Monit. 2012; 34(6): 660–670.
  54. Vanhove T, Annaert P, Kuypers DRJ. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev. 2016; 48(1): 88–112.
  55. Lu TYT, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 2009; 61(4): 482–487.
  56. Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016; 75(5): 795–810.
  57. Constantinescu S, Pai A, Coscia L, et al. Breast-feeding after transplantation. Best Practice & Research Clinical Obstetrics & Gynaecology. 2014; 28(8): 1163–1173.
  58. Bramham K. Diabetic Nephropathy and Pregnancy. Semin Nephrol. 2017; 37(4): 362–369.
  59. Ringholm L, Damm JA, Vestgaard M, et al. Diabetic Nephropathy in Women With Preexisting Diabetes: From Pregnancy Planning to Breastfeeding. Curr Diab Rep. 2016; 16(2): 12.
  60. Mathiesen ER, Ringholm L, Feldt-Rasmussen Bo, et al. Obstetric nephrology: pregnancy in women with diabetic nephropathy--the role of antihypertensive treatment. Clin J Am Soc Nephrol. 2012; 7(12): 2081–2088.
  61. Spotti D. Pregnancy in women with diabetic nephropathy. J Nephrol. 2019; 32(3): 379–388.
  62. American Diabetes Association. 14. Management of Diabetes in Pregnancy: . Diabetes Care. 2019; 42(Suppl 1): S165–S172.
  63. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę, 2019. Stanowisko Polskiego Towarzystwa ogicznego. Diabetol Prakt. 2019; 5: 1–102.
  64. Zhang JJ, Ma XX, Hao Li, et al. A Systematic Review and Meta-Analysis of Outcomes of Pregnancy in CKD and CKD Outcomes in Pregnancy. Clin J Am Soc Nephrol. 2015; 10(11): 1964–1978.
  65. Hanly J. The Nervous System in Systemic Lupus Erythematosus. Systemic Lupus Erythematosus. 2001: 414–428.
  66. Sammaritano LR, Yelnik CM, Porter TF, et al. Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes. Arthritis Rheumatol. 2016; 68(8): 1964–1969.
  67. Buyon JP, Kim MY, Guerra MM, et al. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med. 2015; 163(3): 153–163.
  68. Moroni G, Doria A, Giglio E, et al. Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. J Autoimmun. 2016; 74: 194–200.
  69. Moroni G, Doria A, Giglio E, et al. Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. J Autoimmun. 2016; 74: 6–12.
  70. Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017; 76(3): 476–485.
  71. Cabiddu G, Castellino S, Gernone G, et al. A best practice position statement on pregnancy in chronic kidney disease: the Italian Study Group on Kidney and Pregnancy. J Nephrol. 2016; 29(3): 277–303.
  72. Buyon JP, Kim MY, Guerra MM, et al. Kidney Outcomes and Risk Factors for Nephritis (Flare/) in a Multiethnic Cohort of Pregnant Patients with Lupus. Clin J Am Soc Nephrol. 2017; 12(6): 940–946.
  73. Blom K, Odutayo A, Bramham K, et al. Pregnancy and Glomerular Disease: A Systematic Review of the Literature with Management Guidelines. Clin J Am Soc Nephrol. 2017; 12(11): 1862–1872.
  74. Soh MC, Nelson-Piercy C, Soh MC, et al. High-risk pregnancy and the rheumatologist. Rheumatology (Oxford). 2015; 54(4): 572–587.
  75. Gianfreda D, Quaglini S, Frontini G, et al. Does pregnancy have any impact on long term damage accrual and on the outcome of lupus nephritis? J Autoimmun. 2017; 84: 46–54.
  76. Machen L, Clowse MEB. Vasculitis and Pregnancy. Rheum Dis Clin North Am. 2017; 43(2): 239–247.
  77. Sangle SR, Vounotrypidis P, Briley A, et al. Pregnancy outcome in patients with systemic vasculitis: a single-centre matched case-control study. Rheumatology (Oxford). 2015; 54(9): 1582–1586.



Renal Disease and Transplantation Forum